SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention after a recent rebound that traders say held its gains, with bullish technical setups and positioning ahead of earnings. The upbeat view contrasts with concerns that high rates and a sluggish housing market could continue to weigh on renovation demand.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sharp rally to fresh multi-year highs is drawing attention, with traders citing rotation into defensive, dividend-paying pharma stocks and positioning ahead of the quarterly report. Bulls see a technical breakout and pipeline momentum, while skeptics warn the move may meet resistance and point to patent-expiration and growth concerns.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,397.34014094 USD and is up 0.28 over the last 24 hours. It is currently trading on 12773 active market(s) with $12,152,377,915.37 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin is drawing attention amid concerns over Binances reported major hack and paused withdrawals, with traders debating whether damaged exchange trust could trigger further selling. Others argue the market is absorbing the shock and point to Binances reported reimbursement progress and planned withdrawal reopening as reasons for optimism.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on expected Q3 results and the Phase 3 QUILT-2.005 topline for ANKTIVA plus BCG in BCG-naive bladder cancer; the trial is database-locked, with a supplemental filing planned if results support it. Bullish traders see the readout and ANKTIVAs expanded bladder-cancer label as growth catalysts, while others question commercial uptake and point to competition, short-selling, and broader market weakness to explain the volatility.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders use the leveraged inverse Nasdaq ETF to hedge or bet on further weakness in tech, citing concerns about AI spending and valuations alongside recent tech-led selling. The community is divided: some expect more downside, while others warn that rumors of a U.S.Iran deal and a possible market rebound could reverse gains in the short ETF.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow is being discussed amid volatile, uneven trading across major indexes, with traders watching Fed policy and rising Treasury yields as pressures on equities. Some see relative strength in the Dow as money rotates away from tech, while others warn that inflation, oil-market risks and weakening momentum could deepen a selloff.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Discussion centers on BioCrysts upcoming quarterly results and whether continued ORLADEYO growth can support the stock despite its weak performance. Traders are also looking ahead to Navenibart and Netherton data, while debating managements acquisition strategy and expressing frustration over dilution and limited shareholder returns; buyout talk remains speculative.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results and outlook are drawing attention, with traders highlighting stronger streaming profitability and resilient theme-park performance. The reaction is mixed: some see support for a turnaround, while others point to the stocks persistent range-bound price action and difficulty holding gains.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its upcoming earnings report, with traders watching whether guidance holds and how management addresses pressure on the pharmacy benefit management business. Some see the recent pullback as a potential technical rebound setup, while others remain cautious after the stocks recent selling.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

A sharp volatility spike has lifted UVIX, drawing traders seeking a hedge against a broader market pullback. The community is split between expecting volatility to persistciting concerns about oil, interest rates and geopolitical risksand warning that UVIX can quickly lose value as volatility fades and its leveraged futures exposure decays.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next

Equity

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4

Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.

Futures Drop As Yields, Oil Prices Keep Rising

Futures Drop As Yields, Oil Prices Keep Rising

 Futures are lower - but well off session lows thanks to some well-time oil sell orders just before US traders walked in to work - as bond yields continue to make new highs, with both Nasdaq and Russell lagging the S&P which feels like...

VERA’s TRUTAKNA Stuns in Two-Year Data and Full-Approval Jackpot Is Now in Sight

Vera Therapeutics (NASDAQ:VERA) has delivered the kind of clinical readout that can fundamentally change the investment narrative around a commercial-stage biotech: its TRUTAKNA (atacicept-vymj) program has produced two-year data showing stabilization of kidney function and a dramatic reduction in kidney disease progression in patients with IgA nephropathy (IgAN).

VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics

Vera Therapeutics' Trutakna received an early, fast-tracked approval from the FDA to reduce proteinuria in adults with primary IgA Nephropathy whose health is at risk of deterioration. 


Why Is Vera Therapeutics Stock Gaining Tuesday?

Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease drug Trutakna. Full analysis here.read more...

VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upside

The U.S. Food and Drug Administration is set to announce its decision on Atacicept later on Monday, paving the way for the potential commercialization of the drug in the U.S.

Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment

The biotech moves a step closer to full approval in IgAN as regulators agree to an accelerated timeline for key kidney function data review.

Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA

Pictet Asset Management Holding SA cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392,421 shares of the company's stock after sellin...

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Bearish Sentiment

<ul class="summary-bullets"><li>Biotech still leads year-to-date, with XBI up 26% and IBB up 20%, ahead of SPY’s 12% gain.</li><li>Vera said its kidney drug Trutakna substantially slowed kidney-function decline in the Phase 3 Origin 3 study.</li><li>Ultragenyx is awaiting a Sept.19 FDA decision on UX111, its gene therapy for Sanfilippo syndrome type A.</li></ul><p>Biotech’s 2026 rally cooled this week even as drug developers delivered major clinical updates. Definium Therapeutics (DFTX), Vera Therapeutics (VERA) and GSK (GSK) led the early news cycle, while Ultragenyx Pharmaceutical (RARE) faces the week’s key remaining FDA decision.&nbsp;</p><p>Big Pharma Beats Biotech Sector</p><p>Large-cap healthcare emerged as the relative winner through Tuesday. The&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> gained 1.4% for the week, while the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 1.4%. The&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> slipped 0.5%, compared with declines of 0.9% for the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> and 1.4% for the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>.</p><p><img src="https://news.stocktwits-cdn.com/healthcare_07fe290fdc.png" alt="healthcare.png"></p><p>On Tuesday, XBI dropped 2.3% to $154.03, and IBB fell 1.3% to $202. XLV was nearly flat at $167.67, while SPY and QQQ declined 0.5% and 0.7%, respectively. However, the year-to-date picture still favors biotech: XBI has gained 26% and IBB 20%, compared with 15% for QQQ, 12% for SPY, and 9% for XLV.</p><h2 class="st-heading-2"><strong>Key Biotech Developments So Far This Week&nbsp;</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Day</td><td>Ticker</td><td>Development</td><td>Key Details</td></tr><tr><td>Monday</td><td>DFTX</td><td>Phase 3 anxiety win</td><td>A single 100-microgram dose of DT120 reduced anxiety scores by 9.8 points at week 12, versus 4.7 for placebo. Definium plans a pre-NDA meeting in the fourth quarter and a filing in the first half of 2027.</td></tr><tr><td>Monday</td><td>GSK</td><td>First-line Jideytro data</td><td>In 94 evaluable, previously untreated ROS1-positive lung cancer patients, GSK reported a 94% response rate and 90% progression-free survival at 12 months.</td></tr><tr><td>Monday</td><td>GSK</td><td>Small-cell lung cancer results</td><td>Median overall survival reached 18.5 months with Risvutatug Rezetecan, versus 10.3 months with Topotecan in a China-based Phase 3 trial.</td></tr><tr><td>Monday-Tuesday</td><td>IBRX</td><td>WCLC and H.C. Wainwright participation</td><td>ImmunityBio was on the conference circuit as investors tracked the commercial rollout of Anktiva.</td></tr><tr><td>Tuesday</td><td>VERA</td><td>Confirmatory ORIGIN 3 results</td><td>Mean kidney-function decline at week 52 was 0.1 with Trutakna versus 5.7 with placebo. Vera plans a fourth-quarter filing for traditional approval.</td></tr><tr><td>Tuesday</td><td>GSK</td><td>Chimagen oncology deal</td><td>GSK agreed to acquire a trispecific multiple-myeloma drug in a deal worth up to $750 million.</td></tr><tr><td>Tuesday</td><td>SMMT</td><td>Ivonescimab at WCLC</td><td>Summit and Akeso presented findings from the Harmoni-2 and global Harmoni lung-cancer programs.</td></tr><tr><td>Tuesday</td><td>BNTX, BMY</td><td>Pumitamig at WCLC</td><td>The companies presented data involving their PD-L1/VEGF bispecific antibody.</td></tr><tr><td>Tuesday</td><td>LEGN</td><td>New CEO</td><td>Legend appointed former Novartis executive Ingrid Zhang as CEO</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>What This Week’s Clinical Results Mean&nbsp;</strong></h2><p>Definium Therapeutics’ (DFTX) DT120 is a fast-dissolving formulation of Lysergide, the pharmaceutical form of LSD. Panorama marked its second successful Phase 3 anxiety trial and third positive late-stage study overall, including one in major depressive disorder.</p><p>GSK’s (GSK) Jideytro is already approved for previously treated ROS1-positive lung cancer after receiving an early FDA nod in July. Its next U.S. catalyst is a filing for first-line use this year. GSK is also running a global Phase 3 study of Risvutatug Rezetecan, an antibody-drug conjugate that carries a cancer-killing payload directly to targeted cells.</p><p>The WCLC presentations also highlighted rising competition among PD-(L)1/VEGF bispecific antibodies. Summit Therapeutics’ (SMMT) Ivonescimab and BioNTech (BNTX)-Bristol Myers Squibb’s (BMY) Pumitamig combine immune-checkpoint inhibition with blocking the blood supply tumors need to grow.</p><p>Vera Therapeutics’ (VERA) Origin 3 study measured eGFR, a key indicator of kidney function. Trutakna received accelerated approval in July based on reducing protein in the urine. Meanwhile, ImmunityBio’s (IBRX) main commercial focus is Anktiva, an IL-15-based immune activator approved with BCG for certain patients with bladder cancer.&nbsp;</p><h2 class="st-heading-2"><strong>New FDA Approvals Put Drug Launches In Focus&nbsp;</strong></h2><p>Scholar Rock Holding (SRRK) entered the week with its first commercial product after the FDA approved Isembyld for spinal muscular atrophy patients already receiving an SMN2-directed therapy. The drug targets myostatin, a protein that restricts muscle growth, making it the first approved muscle-targeted SMA treatment.</p><p>Telix Pharmaceuticals (TLX) received approval for Pixclara, a radioactive PET imaging agent designed to distinguish recurrent or progressing glioma from treatment-related changes. AstraZeneca (AZN), meanwhile, said the Phase 3 Serena-4 study of Camizestrant with Pfizer’s Ibrance failed to delay disease progression in first-line advanced breast cancer.&nbsp;</p><h2 class="st-heading-2"><strong>The Week’s Remaining Healthcare Catalysts&nbsp;</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>What To Watch</td></tr><tr><td>Wednesday, Sept. 16</td><td>GPCR, CMPS, ARWR, JSPR, IBRX</td><td>Final Morgan Stanley and H.C. Wainwright sessions</td></tr><tr><td>Wednesday, Sept.16</td><td>FDA PDUFA meeting</td><td>Discussion of future drug-review commitments, staffing, sponsor meetings, and manufacturing assessments.</td></tr><tr><td>Thursday, Sept.17</td><td>CMPS at Deutsche Bank Healthcare Summit</td><td>Commentary on COMP360.</td></tr><tr><td>Thursday, Sept.17</td><td>Fierce Pharma Week and Neuropsychiatric Drug Development Summit</td><td>Final sessions covering commercialization, medical affairs, and neuroscience drug development.</td></tr><tr><td>Friday, Sept.18</td><td>GSK</td><td>No Jideytro decision is pending.</td></tr><tr><td>Saturday, Sept.19</td><td>RARE - UX111</td><td>FDA decision on Ultragenyx’s gene therapy for Sanfilippo syndrome type A.</td></tr></tbody></table></figure></div><p>The FDA’s Wednesday meeting concerns the next reauthorization of the Prescription Drug User Fee Act, under which drugmakers pay fees that help fund regulatory reviews.&nbsp;</p><p>Meanwhile, Ultragenyx’s UX111 is an AAV9 gene therapy for Sanfilippo syndrome type A, an inherited disease that causes progressive and irreversible neurological decline. The firm is seeking accelerated approval and said UX111 would become the first approved treatment for the disease. The FDA’s earlier complete response letter raised concerns about manufacturing and facility-inspection matters. Since the deadline falls on Saturday, the decision could be disclosed on Friday or during the weekend.&nbsp;</p><h2 class="st-heading-2"><strong>What Biotech Investors Should Watch Next Week&nbsp;</strong></h2><p>Merck (MRK) said Monday, Sept.21 is the FDA deadline for an application seeking an updated U.S. label for Winrevair. Winrevair is approved for pulmonary arterial hypertension, a progressive disease involving elevated pressure in the arteries between the heart and lungs.&nbsp;</p><p>Additionally, Sellas Life Sciences (SLS) will present three preclinical studies of SLS009, or Tambiciclib, at the AACR Conference on Pancreatic Cancer from Sept.25 through Sept. 28. SLS009 blocks CDK9, a protein involved in activating genes cancer cells use to grow and survive. Separately, Sellas is continuing its Phase 3 Regal study of Galinpepimut-S (GPS) in acute myeloid leukemia (AML). Its final analysis will be triggered after the prespecified 80th death, and Sellas had recorded 78 events as of May.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-slides-crypto-stocks-decline-as-trump-backed-clarity-act-fails-to-pass-senate-vote/cZto6VyRB2G">Why Did COIN, HOOD, MSTR, ASST, BMNR Stocks Fall Today?&nbsp;</a></p>

AstraZeneca PLC

Definium Therapeutics Inc.

Glaxosmithkline plc - ADR

iShares Biotechnology ETF

Merck & Co Inc

Ultragenyx Pharmaceutical Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$30.98
Prev Close	$30.53
Open	$30.30
Dividend Yield	0.00%
50-Day Moving Average	$32.00
Beta	1.33
Avg. Volume	2.53M
PE Ratio	-5.28

52-Week High	$56.05
52-Week Low	$23.05
Market Capitalization	$2.23B
EPS (Annual)	-$4.66
Price to Book	5.47
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VERA Fundamentals